PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide — PREDEX  

Glucocorticoid-induced Beta-cell Dysfunction Clinical Trial

Official title: Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers

Status Completed

Clinical Trial Summary

The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glucocorticoid-induced Beta-cell Dysfunction
• Glucocorticoid-induced Glucometabolic Abnormalities

• NCT number: NCT00744224
• Study type: Interventional
• Source: VU University Medical Center
• Status: Completed
• Phase: N/A
• Start date: February 2009
• Completion date: January 2010